CEFACLOR ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H14ClN3O4S
Molecular Weight	367.807
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=CC=C3)C(O)=O

InChI

InChIKey=QYIYFLOTGYLRGG-GPCCPHFNSA-N

InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/pro/cefaclor.html
Curator's Comment: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290

Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Canalicular multispecific organic anion transporter 1 21 Target ID: CHEMBL5748 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 8228	1.15 mM [Ki]
Oligopeptide transporter small intestine isoform 6 Target ID: CHEMBL4605 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 8228	4.52 mM [Ki]
Solute carrier family 15 member 2 8 Target ID: CHEMBL1743125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549	Inhibitor 8228	65.0 µM [Ki]
Bacterial penicillin-binding protein 232 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1622180 \| https://www.ncbi.nlm.nih.gov/pubmed/6373702 \| https://www.ncbi.nlm.nih.gov/pubmed/21502633 \| https://www.ncbi.nlm.nih.gov/pubmed/20713676	Inhibitor 8228

Conditions

Condition	Modality	Highest Phase	Product
Otitis media 41 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Curative	Approved 8360	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Lower respiratory tract infections 51 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8360	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Pharyngitis 31 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8360	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Tonsillitis 36 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8360	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Urinary tract infections 204 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8360	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12
Skin and skin structure infections 80 Sources: https://www.drugs.com/pro/cefaclor.html	Curative	Approved 8360	CEFACLOR Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date 1.03109761E12

C_max

Value	Dose	Co-administered	Analyte	Population
17.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
17.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFACLOR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Hypersensitivity... Other AEs: Hypersensitivity (1.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Creatinine serum increased... Other AEs: Creatinine serum increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Aspartate aminotransferase increased, ALT increased... Other AEs: Aspartate aminotransferase increased (1 patient) ALT increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Eosinophilia, Pruritus genital... Other AEs: Eosinophilia (1 patient) Pruritus genital (1 patient) Moniliasis (1 patient) Vaginitis (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Alkaline phosphatase increased, Blood urea increased... Other AEs: Alkaline phosphatase increased (1 patient) Blood urea increased (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Diarrhea... Other AEs: Diarrhea (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Other AEs: Reaction serum sickness-like... Other AEs: Reaction serum sickness-like (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf

AEs

AE	Significance	Dose	Population
Hypersensitivity	1.5%	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Creatinine serum increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
ALT increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Aspartate aminotransferase increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Eosinophilia	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Moniliasis	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Pruritus genital	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Vaginitis	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Alkaline phosphatase increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Blood urea increased	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Diarrhea	1 patient	250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf
Reaction serum sickness-like	0.5%	20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
PEPT2 10 OAT1 595	PEPT2 32 OAT3 333 OAT1 320 PEPT1 48

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OAT1 599	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Ki 1150 uM]
PEPT2 12	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Ki 65 uM]

Drug as victim

Target	Modality	Activity
OAT1 320	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	no
PEPT2 32	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes [Km 70.2 uM]
OAT3 333	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16098483/	yes
PEPT1 48	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/16434549/	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0069	http://www.3bsc.com/index/pro_info.php?id=19425
3B Scientific (Wuhan) Corp	3B1-01441	http://www.3bsc.com/index/pro_info.php?id=21653
AA Blocks	AA00I9K4	https://www.aablocks.com/goods/Goods/detail?id=AA00I9K4
AEchem Scientific Corp., USA	AE065370	https://www.aechemsc.com/info_products/AE065370.php
AHH Chemical co.,ltd	API-1060	http://www.ahhchemical.com/product/API-1060.html
Aaron Chemicals	AR00IABW	http://www.aaronchem.com/53994-73-3
AbMole Bioscience	M5483	http://www.abmole.com/products/cefaclor.html
Achemtek	0104-018667	http://www.achemtek.com/53994-73-3
Acros Organics	AC455260010	https://www.fishersci.com/shop/products/cefaclor-96-acros-organics-1/AC455260010
Acros Organics	AC455260050	https://www.fishersci.com/shop/products/cefaclor-96-acros-organics/AC455260050
Active Biopharma	ABP000537	http://www.activebiopharma.com/53994-73-3
Ambeed	A580945	https://www.ambeed.com/products/53994-73-3.html
ApexBio Technology	A5559	http://www.apexbt.com/cefaclor.html
Aurora Fine Chemicals LLC	A17.879.960	http://online.aurorafinechemicals.com/info?ID=A17.879.960
BLD Pharm	BD00860299	http://www.bldpharm.com/products/143059-69-2.html
BLD Pharm	BD120238	http://www.bldpharm.com/products/53994-73-3.html
BenchChem	B193732	https://www.benchchem.com/product/b193732
BioCrick	BCC2527	http://www.biocrick.com/Cefaclor-BCC2527.html
BioSynth	C-2461	https://www.biosynth.com/products/biochemistry/culture-media-additives/products/C-2461.html
CSNpharm	CSN10559	https://www.csnpharm.com/products/cefaclor.html
Chem Scene	CS-2134	http://www.chemscene.com/53994-73-3.html
Chemspace	CSSB00016993337	https://chem-space.com/CSSB00016993337
Clearsynth	CS-O-06266	https://www.clearsynth.com/en/CSO06266.html
Glentham Life Sciences	GA0871	http://www.glentham.com/products/product/GA0871/
Huateng Pharma	F100322	http://en.huatengsci.com/product/Cefaclor.html
Lab Network	LN01343473	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343473
MedChem Express	HY-B0198	https://www.medchemexpress.com/Cefaclor.html
MuseChem	I003978	https://www.musechem.com/product/I003978.html
Parchem	28476	http://www.parchem.com/chemical-supplier-distributor/Cefaclor-018476.aspx
Sigma-Aldrich	72579_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/72579?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	C6895_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/c6895?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S061062	http://www.sinfoobiotech.com/product/1064465
Smolecule	S523055	http://www.smolecule.com/products/s523055
THE BioTek	bt-263286	https://www.thebiotek.com/product/inhibitors/bt-263286
THE BioTek	bt-308691	https://www.thebiotek.com/product/others/bt-308691
abcr GmbH	AB348868	http://www.abcr.com/shop/en/AB348868
eNovation Chemicals	D964471	https://www.enovationchem.com/ProductDetails.asp?ProductID=D964471
iChemical	EBD2197964	http://www.ichemical.com/products/53994-73-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed

Encouraging good antimicrobial prescribing practice: a review of antibiotic prescribing policies used in the South East Region of England.	2001	11388888
Enterococcal urinary tract infections: eight years experience at a regional hospital in Trinidad, West Indies.	2001 Jan	11779446
The near fatal lick.	2001 Jan	11211712
Drug resistant Haemophilus influenzae from respiratory tract infection in a tertiary care hospital in north India.	2001 Jan-Mar	11370501
Etiologies of the urinary tract infections in a Yemeni City.	2001 Jul	11479641
What have we learned from pharmacokinetic and pharmacodynamic theories?	2001 Mar 15	11249828
Tests for 2 x K contingency tables with clustered ordered categorical data.	2001 Mar 15	11241576
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). I. Susceptibility distribution].	2001 May	11510118
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.	2001 Oct	11581436
Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase.	2001 Sep 7	11443136
Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000.	2002	11951998
Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans.	2002 Apr	11936565
Immunoglobulin E binding determinants on beta-lactam drugs.	2002 Aug	12130943
An unusual abdominal mass in a renal transplant recipient.	2002 Dec	12535266
Foreign drug firm pleads guilty to felony charges.	2002 Jan-Feb	11881596
Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries.	2002 Jul	12077154
Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000.	2002 Jun	12111576
Trends in antimicrobial susceptibility of the Streptococcus milleri group.	2002 Jun	12111565
The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections.	2002 Mar	11932140
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.	2002 Mar	11850285
Serum sickness-like reactions.	2002 May	12041822
An evaluation of cefaclor in Pakistani children with pharyngotonsillitis.	2002 Oct	12553673
The Italian Epidemiological Survey 1997-1999. Antimicrobial susceptibility data of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis in Italy.	2002 Oct	12385682
Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000.	2002 Sep	12239225
Antimicrobial action of Nitens mouthwash (cetyltrimethylammonium naproxenate) on multiple isolates of pharyngeal microbes: a controlled study against chlorhexidine, benzydamine, hexetidine, amoxicillin, amoxicillin-clavulanate, clarithromycin, and cefaclor.	2002 Sep	12218263
Drainage of liver abscess via laparoscopic trocar with local anesthesia.	2003 Apr	12709620
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea.	2003 Apr	12654765
Life-threatening infantile diarrhea from fluoroquinolone-resistant Salmonella enterica typhimurium with mutations in both gyrA and parC.	2003 Feb	12604000
Etiology of acute otitis media in childhood and evaluation of two different protocols of antibiotic therapy: 10 days cefaclor vs. 3 days azitromycin.	2003 Jan	12560149
Sensitive determination of a beta-lactam antibiotic, cefaclor by liquid chromatography with chemiluminescence detection.	2003 Jan 15	12485718
Antimicrobial resistance in Gram-negative bacteria from Intensive Care Units and Urology Services. A nationwide study in The Netherlands 1995-2000.	2003 Jun	12791468
Reactive metabolites and adverse drug reactions: clinical considerations.	2003 Jun	12721394
How can we predict bacterial eradication?	2003 Mar	12839703
A comparative study of cefaclor vs amoxicillin/clavulanate in pediatric pharyngotonsillitis.	2003 Mar	12640354
[Sensitivity of Haemophilus influenzae isolates in Spain to 17 oral antibiotics].	2003 Mar	12586017
Antibiotic prophylaxis by low-dose cefaclor in children with vesicoureteral reflux.	2003 May	12736811
Rapid and sensitive high-performance liquid chromatographic determination of four cephalosporin antibiotics in pharmaceuticals and body fluids.	2003 May 5	12668080
[Hypersensitivity reactions to beta-lactam antibiotics in childhood].	2003 May-Jun	12783760
Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States.	2003 Spring	12705682

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.

Route of Administration: Oral

In Vitro Use Guide

Cefaclor inhibits the gram-negative bacteria. At a level of 12.5 ug/ml, 73% of the E. coli, 90% of the Salmonella, 55% of the Shigella, 77% of the Citrobacter, 91% of the Klebsiella, and 75% of the P. mirabilis isolates were inhibited. However, only 18% of the Enterobacter, 3% of the Serratia, 9% of the Proteus morganii, and 16% of the Providencia strains, and less than 10% of the Proteus vulgaris, Proteus rettgeri, and Bacteroides fragilis isolates, were inhibited. All Pseudomonas strains were as resistant to cefaclor as they were to available cephalosporins.

Name

Type

Language

CEFACLOR ANHYDROUS

Common Name

English

Cefaclor [WHO-DD]

Common Name

English

CEFACLOR IMPURITY C [EP IMPURITY]

Common Name

English

CEFACLOR [MI]

Common Name

English

cefaclor [INN]

Common Name

English

CEFACLOR [JAN]

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2R)-2-AMINO-2-PHENYLACETYL)AMINO)-3-CHLORO-8-OXO-, (6R,7R)-

Common Name

English

(6R,7R)-7-(((2R)-2-AMINO-2-PHENYLACETYL)AMINO)-3-CHLORO-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

NDF-RT

N0000175488